Compare INTZ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | CVKD |
|---|---|---|
| Founded | 1983 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 13.8M |
| IPO Year | 2020 | 2022 |
| Metric | INTZ | CVKD |
|---|---|---|
| Price | $0.76 | $5.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 90.4K | 61.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,015,000.00 | N/A |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.73 | $4.21 |
| 52 Week High | $2.64 | $15.99 |
| Indicator | INTZ | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 46.18 |
| Support Level | N/A | $4.91 |
| Resistance Level | $1.20 | $6.09 |
| Average True Range (ATR) | 0.05 | 0.74 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 11.80 | 14.91 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.